Here, we revealed the co-occurrence of EGFR amplification and CDKN2A deletion in patients with glioma, suggesting that the poor drug response of EGFR inhibitors in glioma may be associated with CDKN2A deletion. This evidence concerns the gene CDKN2A and central nervous system cancer.